Drug intelligence / Profile preview

AXT-1007

Development stage: Preclinical
Lead developer: Axter Therapeutics
Modality: Small Molecules

Overview

AXT-1007 is a small molecule modulator of the Orexin 2 receptor (OX2R) currently under development by Axter Therapeutics. The compound is in the IND-enabling phase, targeting sleep disorders and depression. By modulating OX2R signaling, AXT-1007 aims to address the underlying neurobiology of arousal and mood regulation. While the specific functional direction (agonism vs. antagonism) has not been publicly detailed, OX2R is a validated target for sleep-wake cycle management and neuropeptide-mediated mood stabilization.

Targets

HCRTR2 (Orexin/hypocretin receptor type 2)

Beyond the preview

Go deeper on AXT-1007.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AXT-1007.

Explore the full profile